Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatoprotective Measures for Children at High Risk of NAFLD
NCT06918080Phase 4Active, not recruiting
- Sponsor
- Ain Shams University
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ursodeoxycholic acid in non-alcoholic fatty liver disease (NAFLD), sponsored by Ain Shams University. Primary endpoint: Prevalence of liver steatosis among the study population by using LIVERFASt at 2 years. Started Nov 2023; status: active, not recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06918080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918080.